

Radavirsen performs well in early influenza trial

September 20 2017

A phase 1 clinical trial published in the *British Journal of Clinical Pharmacology* found that radavirsen—an antisense oligomer that inhibits the production of certain influenza proteins—is safe and well-tolerated in healthy individuals. Additional studies on radavirsen's potential as a treatment for influenza are warranted

In the 56-participant trial, pharmacokinetic analyses indicated that at 8mg/kg, radavirsen is expected to be effective in the treatment of influenza.

"This is the first demonstration of the safety and tolerability and pharmacokinetics of an [antisense oligonucleotide](#) for the treatment of influenza A," wrote the authors of the study.

More information: John H. Beigel et al, Safety, Tolerability, and Pharmacokinetics of Radavirsen (AVI-7100), an Antisense Oligonucleotide Targeting Influenza A M1/M2 translation, *British Journal of Clinical Pharmacology* (2017). [DOI: 10.1111/bcp.13405](https://doi.org/10.1111/bcp.13405)

Provided by Wiley

Citation: Radavirsen performs well in early influenza trial (2017, September 20) retrieved 10 April 2024 from <https://medicalxpress.com/news/2017-09-radavirsen-early-influenza-trial.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.